J. Lee

发表

Belotecan, new camptothecin analogue, is active in patients with small-cell lung cancer: results of a multicenter early phase II study.

D. Heo, C. Suh, J. H. Lee, 2008, Annals of oncology : official journal of the European Society for Medical Oncology.

IMpower133: Updated overall survival (OS) analysis of first-line (1L) atezolizumab (atezo) + carboplatin + etoposide in extensive-stage SCLC (ES-SCLC)

N. Reinmuth, Ying Cheng, A. Mansfield, 2019, Annals of Oncology.

Nivolumab with carboplatin, paclitaxel, and bevacizumab for first-line treatment of advanced non-squamous non-small cell lung cancer.

M. Nishio, N. Yamamoto, T. Tamura, 2021, Annals of Oncology.

LBA54 Randomized phase III trial of nivolumab in combination with carboplatin, paclitaxel, and bevacizumab as first-line treatment for patients with advanced or recurrent non-squamous NSCLC

Teruhiko Yoshida, Y. Ohe, M. Nishio, 2020 .

Safety and patient-reported outcomes of atezolizumab, carboplatin, and etoposide in extensive-stage small-cell lung cancer (IMpower133): a randomized phase I/III trial.

A. Mansfield, F. Kabbinavar, C. Quach, 2020, Annals of oncology : official journal of the European Society for Medical Oncology.

A phase I / II trial of docetaxel, capecitabine, and cisplatin as a first line chemotherapy for advanced gastric cancer

J. Yook, M. Ryu, J. Lee, 2004 .

First-line nivolumab + ipilimumab in advanced NSCLC: CheckMate 227 subpopulation analyses in Asian patients

K. O'Byrne, F. Nathan, K. Lee, 2022, ESMO open.

Long-term survival with first-line nivolumab plus ipilimumab in patients with advanced non-small cell lung cancer: a pooled analysis.

K. O'Byrne, S. Ramalingam, M. Hellmann, 2022, Annals of oncology : official journal of the European Society for Medical Oncology.

A single institutional phase III trial of preoperative chemotherapy with hyperfractionation radiotherapy plus surgery versus surgery alone for resectable esophageal squamous cell carcinoma.

J. Lee, J. Kim, S. Park, 2004, Annals of oncology : official journal of the European Society for Medical Oncology.

1258O Amivantamab (JNJ-61186372), an EGFR-MET bispecific antibody, in combination with lazertinib, a 3rd-generation tyrosine kinase inhibitor (TKI), in advanced EGFR NSCLC

E. Cho, J. Infante, B. Cho, 2020 .

Phase II study of erlotinib as a salvage treatment for non-small-cell lung cancer patients after failure of gefitinib treatment.

D. Lee, S. Kim, J. Lee, 2008, Annals of oncology : official journal of the European Society for Medical Oncology.

A phase II study of paclitaxel and capecitabine as a first-line combination chemotherapy for advanced gastric cancer

J. Yook, M. Ryu, J. Lee, 2008, British Journal of Cancer.

Efficacy and safety of BI 1482694 (HM61713), an EGFR mutant‐specific inhibitor, in T790M‐positive NSCLC at the recommended phase II dose: 1300

E. Cho, Y. Min, J.-Y. Han, 2016, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

120O Pembrolizumab (Pembro) with or without lenvatinib (Lenva) in first-line metastatic NSCLC with PD-L1 TPS ≥1% (LEAP-007): A phase III, randomized, double-blind study

L. Livi, T. Mekhail, T. Csoszi, 2021, Annals of Oncology.

EP08.02-140 MET Biomarker-based Preliminary Efficacy Analysis in SAVANNAH: savolitinib+osimertinib in EGFRm NSCLC Post-Osimertinib

L. Sequist, S. Novello, F. de Marinis, 2022, Journal of Thoracic Oncology.

VP3-2022: Pembrolizumab (pembro) versus placebo for early-stage non-small cell lung cancer (NSCLC) following complete resection and adjuvant chemotherapy (chemo) when indicated: Randomized, triple-blind, phase III EORTC-1416-LCG/ETOP 8-15 – PEARLS/KEYNOTE-091 study

U. Dafni, R. Stahel, M. Mauer, 2022, Annals of Oncology.

930MO PD-L1 expression and outcomes of pembrolizumab and placebo in completely resected stage IB-IIIA NSCLC: Subgroup analysis of PEARLS/KEYNOTE-091

U. Dafni, R. Stahel, M. Mauer, 2022, Annals of Oncology.

4O Nivolumab (NIVO) + ipilimumab (IPI) versus chemotherapy (chemo) as first-line (1L) treatment for advanced NSCLC (aNSCLC) in CheckMate 227 part 1: Efficacy by KRAS, STK11, and KEAP1 mutation status

K. O'Byrne, S. Ramalingam, M. Hellmann, 2021, Annals of Oncology.

459MO Phase Ia study to evaluate GDC-6036 monotherapy in patients with solid tumors with a KRAS G12C mutation

M. Krebs, H. Prenen, J. Lee, 2022, Annals of Oncology.

Phase II study of capecitabine and cisplatin as first-line combination therapy in patients with gastric cancer recurrent after fluoropyrimidine-based adjuvant chemotherapy

J. Yook, M. Ryu, J. Lee, 2005, British Journal of Cancer.

A phase I / II trial of docetaxel, capecitabine, and cisplatin as a first line chemotherapy for advanced gastric cancer.

J. Yook, M. Ryu, J. Lee, 2004, Journal of Clinical Oncology.

55P Final results from the NIFTY trial, a phase IIb, randomized, open-label study of liposomal Irinotecan (nal-IRI) plus fluorouracil (5-FU)/leucovorin (LV) in patients (pts) with previously treated metastatic biliary tract cancer (BTC)

G. Abou-Alfa, J. Lee, B. Ryoo, 2022, Annals of Oncology.

Osimertinib vs standard of care (SoC) EGFR-TKI as first-line therapy in patients (pts) with untreated EGFRm advanced NSCLC: FLAURA post-progression outcomes.

D. Planchard, A. Dechaphunkul, M. Boyer, 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

128O Osimertinib vs standard of care (SoC) EGFR-TKI as first-line therapy in patients (pts) with untreated EGFRm advanced NSCLC: FLAURA post-progression outcomes

Y. Ohe, D. Planchard, A. Dechaphunkul, 2018 .

JNJ-61186372 (JNJ-372), an EGFR-cMET bispecific antibody, in advanced non-small cell lung cancer (NSCLC): An update on phase I results.

E. Cho, K. Bae, E. Attiyeh, 2018, Annals of Oncology.

122MO Nivolumab (NIVO) + ipilimumab (IPI) as first-line (1L) treatment (tx) for patients (pts) with advanced NSCLC (aNSCLC) and baseline (BL) brain metastases (mets): Intracranial and systemic outcomes from CheckMate 227 Part 1

K. O'Byrne, M. Hellmann, H. Borghaei, 2021, Annals of Oncology.

Phase II study of capecitabine and cisplatin as first-line combination therapy in patients with gastric cancer recurrent after fluoropyrimidine-based adjuvant chemotherapy

M. Ryu, J. Lee, Y. Kang, 2005, British Journal of Cancer.

Ceritinib in ROS1-rearranged non-small-cell lung cancer: a Korean nationwide phase II study

M. Ahn, E. Cho, B. Cho, 2016 .